Stock listing

LS Exchange:A2ALUN SynAct Pharma AB Aktie

German listing (LS Exchange) of SynAct Pharma AB · home listing Stockholm:SYNACT

Follow SynAct Pharma AB into a list and get an email when it puts out news.

Home listing price · OMXSTO:SYNACT

16.22 SEK -0.54 (-3.2%)

Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:SYNACT

Past year -29.6% · daily closes, Oct 30, 2025 – Oct 30, 2026, adjusted for splits
Day range
15.86 – 16.98 SEKOct 30, 2026
Volume
153,318 sharesOct 30, 2026
Market cap
908.3M SEKAt the close on Oct 30, 2026 · price × 56.00M shares outstanding
52-week range
7.05 – 24.60 SEKLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
Traded on an average day
2.63M SEKMedian day 91,565 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
SynAct Pharma AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:SYNACT · Home16.22 SEK-0.54 (-3.2%)153,31816.9816.9815.8616.76Close on Oct 30, 2026
Frankfurt:8F8€1.45 EUR-0.224 (-13.4%)—€1.49€1.494€1.45€1.674Close on Oct 30, 2026

Daily closes

Last 3 months, Jul 30, 2026 – Oct 30, 2026 · OMXSTO:SYNACT · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
16.22-0.54-3.2%16.9816.9815.86153,318
16.76-0.72-4.1%17.4817.6816.7684,109
17.48-0.52-2.9%18.0018.1817.4094,608
18.00+0.14+0.8%17.3019.8017.30249,815
17.86+0.62+3.6%17.1018.2616.90118,908
17.24-0.16-0.9%17.4217.6016.8669,444
17.40-0.04-0.2%17.1617.5017.0047,178
17.44+0.28+1.6%17.1617.6017.0037,888
17.16+0.22+1.3%16.8017.5816.7862,065
16.94-0.06-0.4%16.9017.3016.4272,990
17.00+0.04+0.2%16.9617.7016.6634,266
16.96-0.04-0.2%16.8417.0016.2438,380
17.00-0.20-1.2%16.9417.1416.8026,865
17.20-0.02-0.1%17.0417.4816.8050,643
17.22+0.32+1.9%16.9017.3016.8049,450
16.900.000.0%16.7817.1816.5276,409
16.90-0.28-1.6%17.7617.7616.7268,887
17.18-0.04-0.2%16.9817.4416.7647,743
17.22+0.10+0.6%17.1217.7616.9840,546
17.12-0.68-3.8%17.5017.7217.0847,994
17.80+0.62+3.6%17.0417.8016.8279,638
17.18-0.32-1.8%17.8017.8016.90135,732
17.50-0.16-0.9%17.8018.0017.4268,631
17.66-0.02-0.1%17.7017.8417.3845,694
17.68+0.38+2.2%17.4017.8417.2060,968
17.30-0.16-0.9%17.5618.0617.00171,228
17.46-0.10-0.6%17.8018.0017.3655,745
17.56-0.34-1.9%17.8818.2817.5477,862
17.900.000.0%17.8818.0017.6065,810
17.90-0.06-0.3%17.9618.0417.38147,788
17.96-0.22-1.2%18.1818.2017.8069,609
18.18-0.36-1.9%18.6618.6617.8069,266
18.54+0.24+1.3%18.2018.6417.00297,291
18.30-0.32-1.7%18.4818.5018.2033,702
18.62-0.34-1.8%18.9619.0018.2861,725
18.96-0.08-0.4%19.1019.3018.48105,457
19.04-0.14-0.7%18.9019.4418.8096,715
19.18-0.48-2.4%19.4019.5018.78123,379
19.66+0.40+2.1%19.2819.7619.02190,369
19.26+1.76+10.1%17.5020.0517.20476,203
17.50+0.06+0.3%17.6217.9616.84634,397
17.44-2.48-12.4%18.7819.0017.42502,924
19.92-0.53-2.6%20.3022.4519.68949,027
20.45+0.45+2.2%20.0020.6019.68118,315
20.00+0.08+0.4%19.9420.3019.60126,760
19.92+0.48+2.5%19.4220.0019.12168,843
19.44+0.42+2.2%19.2019.7619.2098,705
19.02-0.64-3.3%19.4619.8818.9876,380
19.66+0.66+3.5%19.1819.9419.1091,565
19.00-0.84-4.2%19.9420.0018.7479,321
19.84+0.52+2.7%19.3220.0019.1469,317
19.32-2.13-9.9%20.4521.0518.90322,742
21.45+1.45+7.2%20.5022.2020.50447,400
20.00+0.22+1.1%19.7620.0019.2859,018
19.78-0.16-0.8%19.9420.0019.36109,127
19.94-0.21-1.0%20.1020.5019.36124,770
20.15+0.85+4.4%19.1620.6019.02180,150
19.30+0.74+4.0%18.8019.3018.46176,140
18.56-0.26-1.4%18.5019.0018.3685,963
18.82+0.02+0.1%18.6419.0018.2668,091
18.80-0.34-1.8%19.2219.4418.54114,074
19.14-0.32-1.6%19.5420.0019.1493,796
19.46+0.36+1.9%19.0620.1518.76343,047
19.10+1.04+5.8%17.8819.1017.8497,312
18.06-0.20-1.1%18.3018.4017.7094,809
18.26+0.44+2.5%17.9818.6017.74145,816
17.82+0.42+2.4%17.2618.2017.12154,259
Ticker
LS Exchange:A2ALUN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LS Exchange
Currency
EUR

What changed lately

Latest news

SynAct Pharma to Participate in Investor and Partnering Conferences

Sep 22, 2026

Closed 17.90 (0.0%) on Sep 22, 2026

WHO Identifies Resomelagon as One Of Six Dengue Drug Candidates with Evidence Supporting Further Clinical Development

Sep 16, 2026

Closed 18.54 (+1.3%) on Sep 16, 2026

Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results and Supports Phase 3 Development - FDA Discussions on Trial Design Planned for Q4 2026

Sep 7, 2026

Closed 19.26 (+10.1%) on Sep 7, 2026

SynAct Pharma's CEO and CSO Sell Shares

Sep 3, 2026

Closed 17.44 (-12.4%) on Sep 3, 2026

SynAct Pharma publishes Q2 2026 interim results

Aug 20, 2026

Closed 19.32 (-9.9%) on Aug 20, 2026

SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation

Aug 5, 2026

Closed 19.46 (+1.9%) on Aug 5, 2026

SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness

Jul 20, 2026

Closed 18.60 (-5.5%) on Jul 20, 2026

Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering

Jun 15, 2026

Closed 12.10 (-16.6%) on Jun 15, 2026

Notice of annual general meeting in SynAct Pharma AB

May 7, 2026

Closed 15.04 (+3.0%) on May 7, 2026

SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout

May 6, 2026

Closed 14.60 (-8.8%) on May 6, 2026

All SynAct Pharma AB news

Decks

SynAct Pharma AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 20 in all · newest Sep 22, 2026 · oldest 2026
Decks
22 decks · latest September 2026

Where SynAct Pharma AB is listed

ListingExchangeCountryCurrency
Stockholm:SYNACT · Home listingStockholmSwedenSEK
Aquis:SYNACSAquisUnited KingdomSEK
LS Exchange:A2ALUN · This pageLS ExchangeGermanyEUR
Lang & Schwarz:A2ALUNLang & SchwarzGermanyEUR
Frankfurt:8F8FrankfurtGermanyEUR
gettex:8F8gettexGermanyEUR
Aquis:SYNACSAquisUnited KingdomSEK
Munich:8F8MunichGermanyEUR
Stuttgart:8F8StuttgartGermanyEUR
Tradegate:8F8TradegateGermanyEUR

Log in to ask 6ix AI your own questions about SynAct Pharma AB.